bloom research semaglutide BloomMD and produced in a GMP Semaglutide - Bloom24now

The FDAs decision was based on results from the companys OASIS 4 trial, which showed that the pills weight-loss efficacy was comparable to that of the injectable form

A 42-year-old female with longstanding profound fatigue, chronic pain, asthma, multiple food intolerances, GI symptoms including diarrhea, urticaria, food cravings, weight gain, and migraine who was essentially housebound due to constant exhaustion (she estimated 30% of normal energy) took tirzepitide at 3.75 mg principally to address obesity

Arul, V., et al

Our commitment to patient safety and rights ensures that individuals receive ethical and compassionate care